The Department of Health has confirmed that the National Institute for Health and Clinical Excellence will be fully responsible for the assessment of medicines when the new value-based pricing (VBP) system comes into effect.
The information is set out in the DoH’s response to a report on the future role of the NICE, published in January by the Health Select Committee. However, the DoH has still not released the details of the VBP system, which is due to come into effect in January 2014, despite calls by the committee to finalise the system by the end of this month (March 2013).
Sir Andrew Dillon, chief executive of NICE, said: “We welcome the opportunity to take the central role in VBP and we look forward to working with the DoH and our stakeholders in developing the methods and processes for the new system.”
In its response, the DoH gives more information on the Cancer Drugs Fund, which is set to finish when the VBP system is implemented. Patients receiving medicines through the fund will be protected, the DoH says.
In addition, a small number of drugs made available through the fund could be assessed under the VBP system — which will otherwise assess only drugs launched from 2014 onwards —and data collected from the Cancer Drugs Fund could be used to support this process.
Also mentioned in the response are plans to set out an integrated approach to commissioning in a “Common purpose framework”, which will be published this spring and will include an outline of NICE’s role in supporting commissioning.
From 1 April 2013 NICE will have the additional responsibility of producing guidance and quality standards for social care and, to reflect this, its name is changing to the National Institute for Health and Care Excellence.
Friday, March 22, 2013
NICE to take full charge of value-based pricing | PJ Online